Silverarc Capital Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Silverarc Capital Management, LLC reported 65 stock positions worth $405.1 million. Its top holding was Merus (MRUS) at 9.1% of the portfolio, followed by Nuvalent Class A (NUVL, 8.7%) and Avidity Biosciences (RNAM, 5.2%). Compared with Q1 2024, it opened 13 new positions, sold out of 20, added to 27 and reduced 10. The biggest buy was Nuvalent Class A (NUVL, shares +195%) and the biggest sale Solid Biosciences (SLDB, shares −64%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $405.1M (Q2 2024)
- SEC Filing
- 0001420506-24-001528 ↗ filed Aug 14, 2024
Holdings Value
Holdings 65 stocks · $405.1M
| MRUS Merus NV | 9.11% | 623,628 | $36.9M | Add +10.1% |
| NUVL Nuvalent Inc. Class A | 8.72% | 465,710 | $35.3M | Add +195.2% |
| RNAM Avidity Biosciences Inc. | 5.22% | 517,734 | $21.1M | Add +5.8% |
| URGN Urogen Pharma Ltd. | 4.57% | 1,102,000 | $18.5M | Add +116.7% |
| ERAS Erasca Inc. | 4.55% | 7,816,926 | $18.4M | Add +3392.1% |
| MORF Morphic Holding Inc. | 4.09% | 486,306 | $16.6M | Add +0.5% |
| AKRO Akero Therapeutics Inc. | 3.62% | 625,087 | $14.7M | Add +56.3% |
| CLDX Celldex Therapeutics Inc. | 3.43% | 374,910 | $13.9M | Add +25.3% |
| ITCI Intra-Cellular Therapies Inc. | 3.25% | 192,345 | $13.2M | Add +452.6% |
| PSTX Poseida Therapeutics Inc. | 2.60% | 3,607,999 | $10.5M | Add +0.3% |
| COGT Cogent Biosciences Inc. | 2.51% | 1,206,214 | $10.2M | Add +16.4% |
| INSM Insmed Inc. | 2.32% | 140,000 | $9.4M | Add +23.2% |
| ALNY Alnylam Pharmaceuticals Inc. | 2.16% | 36,000 | $8.7M | New |
| ELUT Elutia Inc. | 1.96% | 1,603,580 | $8.0M | Add +1940.7% |
| CRBP Corbus Pharmaceuticals Holdi | 1.93% | 172,492 | $7.8M | Add +439.4% |
| ORIC Oric Pharmaceuticals Inc. | 1.88% | 1,075,812 | $7.6M | Reduce -3.3% |
| SNDX Syndax Pharmaceuticals Inc. | 1.88% | 370,000 | $7.6M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 1.87% | 184,662 | $7.6M | Add +0.5% |
| CCCC C4 Therapeutics Inc. | 1.65% | 1,442,841 | $6.7M | Add +0.5% |
| SRPT Sarepta Therapeutics Inc. | 1.64% | 42,000 | $6.6M | New |
| KALV Kalvista Pharmaceuticals Inc. | 1.63% | 560,883 | $6.6M | Reduce -0.1% |
| VCYT Veracyte Inc. | 1.51% | 282,248 | $6.1M | Add +0.5% |
| ABVX Abivax SA-ADR | 1.49% | 455,800 | $6.0M | Add +507.7% |
| OLMA Olema Pharmaceuticals Inc. | 1.46% | 546,863 | $5.9M | Add +6.1% |
| ADCT Adc Therapeutics SA | 1.38% | 1,768,770 | $5.6M | Add +252.9% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.26% | 500,000 | $5.1M | No change |
| MERSANA THERAPEUTICS INC | 1.24% | 2,500,585 | $5.0M | Reduce -15.8% |
| GOSS Gossamer Bio Inc. | 1.22% | 5,500,000 | $5.0M | Reduce -10.3% |
| TELA Tela Bio Inc. | 1.16% | 1,000,000 | $4.7M | Add +28.7% |
| IRON Disc Medicine Inc. | 1.13% | 101,187 | $4.6M | New |
| BIIB Biogen Inc. | 1.11% | 19,365 | $4.5M | No change |
| VRNA Verona Pharma Ltd. | 1.09% | 304,633 | $4.4M | Add +122.8% |
| GERN Geron Corp. | 1.05% | 999,270 | $4.2M | Add +299.7% |
| BHVN Biohaven Ltd. | 0.86% | 100,000 | $3.5M | New |
| LBPH Longboard Pharmaceuticals Inc. | 0.82% | 122,849 | $3.3M | New |
| PRAX Praxis Precision Medicines I | 0.69% | 67,296 | $2.8M | Reduce -64.7% |
| GPCR Structure Therapeutics Inc. | 0.68% | 70,516 | $2.8M | Add +605.2% |
| BDSX Biodesix Inc. | 0.68% | 1,808,959 | $2.8M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.67% | 79,194 | $2.7M | No change |
| SLDB Solid Biosciences Inc. | 0.66% | 472,995 | $2.7M | Reduce -64.3% |
| CATX Perspective Therapeutics Inc. | 0.64% | 260,009 | $2.6M | New |
| CERS Cerus Corp. | 0.64% | 1,465,744 | $2.6M | No change |
| CGEN Compugen Ltd. | 0.62% | 1,501,113 | $2.5M | Add +50.1% |
| TRVI Trevi Therapeutics Inc. | 0.62% | 844,235 | $2.5M | No change |
| KOD Kodiak Sciences Inc. | 0.62% | 1,062,062 | $2.5M | Reduce -14.3% |
| JSPR Jasper Therapeutics Inc. | 0.62% | 109,892 | $2.5M | No change |
| ENGN Engene Holdings Inc. | 0.61% | 263,841 | $2.5M | New |
| WVE Wave Life Sciences Ltd. | 0.61% | 495,471 | $2.5M | No change |
| FULC Fulcrum Therapeutics Inc. | 0.61% | 398,436 | $2.5M | No change |
| EVOGENE LTD | 0.49% | 3,079,739 | $2.0M | Reduce -0.2% |
| STOK Stoke Therapeutics Inc. | 0.47% | 141,518 | $1.9M | New |
| MGNX Macrogenics Inc. | 0.39% | 370,000 | $1.6M | Reduce -22.6% |
| MODULAR MED INC | 0.35% | 900,000 | $1.4M | No change |
| ZURA Zura Bio Ltd. | 0.28% | 328,504 | $1.1M | No change |
| TARS Tarsus Pharmaceuticals Inc. | 0.27% | 40,000 | $1.1M | New |
| VYNE THERAPEUTICS INC | 0.23% | 467,397 | $921K | Add +441.1% |
| EYPT Eyepoint Inc. | 0.21% | 100,000 | $870K | Reduce -59.7% |
| ETNB 89BIO Inc. | 0.18% | 92,298 | $739K | No change |
| MTEMQ Molecular Templates Inc. | 0.18% | 623,838 | $717K | Add +75.9% |
| GUTS Fractyl Health Inc. | 0.18% | 166,666 | $712K | No change |
| SLNO Soleno Therapeutics Inc. | 0.15% | 15,000 | $612K | New |
| KPTI Karyopharm Therapeutics Inc. | 0.12% | 558,466 | $485K | No change |
| RLMD Relmada Therapeutics Inc. | 0.07% | 99,379 | $298K | No change |
| ALGS Aligos Therapeutics Inc. | 0.06% | 655,515 | $229K | No change |
| PCVX Vaxcyte Inc. | 0.05% | 2,500 | $189K | New |
Options reported separately and not counted above: INSMED INC calls ($16.8M), ALX ONCOLOGY HLDGS INC puts ($1.0M), C4 THERAPEUTICS INC calls ($693K), MERSANA THERAPEUTICS INC calls ($338K).
Other holdings (1): bonds, preferreds, convertibles and warrants · $6K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $6K | No change |
Total filed on the 13F, all lines: $405.1M.
Portfolio Sells Q1 2024 → Q2 2024
| SLDB Solid Biosciences Inc. | Reduce -64.3% | 0.66% | −4.29 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −2.71 |
| PRAX Praxis Precision Medicines I | Reduce -64.7% | 0.69% | −2.57 |
| MERSANA THERAPEUTICS INC | Reduce -15.8% | 1.24% | −2.49 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -3.3% | 1.88% | −2.41 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −2.21 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −1.68 |
| MGNX Macrogenics Inc. | Reduce -22.6% | 0.39% | −1.59 |
| BOLD Boundless Bio Inc. | Sold out | 0.00% | −1.25 |
| EYPT Eyepoint Inc. | Reduce -59.7% | 0.21% | −1.22 |
| KOD Kodiak Sciences Inc. | Reduce -14.3% | 0.62% | −1.21 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −0.99 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.98 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.93 |
| GOSS Gossamer Bio Inc. | Reduce -10.3% | 1.22% | −0.81 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −0.80 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −0.78 |
| PLRX Pliant Therapeutics Inc. | Sold out | 0.00% | −0.77 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −0.76 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.66 |
| KRYS Krystal Biotech Inc. | Sold out | 0.00% | −0.50 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.46 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −0.46 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.40 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -0.1% | 1.63% | −0.24 |
| ACET Adicet Bio Inc. | Sold out | 0.00% | −0.22 |
| MLYS Mineralys Therapeutics Inc. | Sold out | 0.00% | −0.21 |
| EVOGENE LTD | Reduce -0.2% | 0.49% | −0.15 |
| RZLT Rezolute Inc. | Sold out | 0.00% | −0.11 |
| IMNM Immunome Inc. | Sold out | 0.00% | −0.05 |
Portfolio Buys Q1 2024 → Q2 2024
| NUVL Nuvalent Inc. Class A | Add +195.2% | 8.72% | +5.40 |
| ERAS Erasca Inc. | Add +3392.1% | 4.55% | +4.42 |
| ITCI Intra-Cellular Therapies Inc. | Add +452.6% | 3.25% | +2.58 |
| URGN Urogen Pharma Ltd. | Add +116.7% | 4.57% | +2.43 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 2.16% | +2.16 |
| MRUS Merus NV | Add +10.1% | 9.11% | +1.96 |
| ELUT Elutia Inc. | Add +1940.7% | 1.96% | +1.89 |
| SNDX Syndax Pharmaceuticals Inc. | New | 1.88% | +1.88 |
| RNAM Avidity Biosciences Inc. | Add +5.8% | 5.22% | +1.72 |
| SRPT Sarepta Therapeutics Inc. | New | 1.64% | +1.64 |
| CRBP Corbus Pharmaceuticals Holdi | Add +439.4% | 1.93% | +1.57 |
| INSM Insmed Inc. | Add +23.2% | 2.32% | +1.45 |
| ABVX Abivax SA-ADR | Add +507.7% | 1.49% | +1.19 |
| IRON Disc Medicine Inc. | New | 1.13% | +1.13 |
| BHVN Biohaven Ltd. | New | 0.86% | +0.86 |
| LBPH Longboard Pharmaceuticals Inc. | New | 0.82% | +0.82 |
| GERN Geron Corp. | Add +299.7% | 1.05% | +0.81 |
| AKRO Akero Therapeutics Inc. | Add +56.3% | 3.62% | +0.79 |
| ADCT Adc Therapeutics SA | Add +252.9% | 1.38% | +0.75 |
| BDSX Biodesix Inc. | New | 0.68% | +0.68 |
| CATX Perspective Therapeutics Inc. | New | 0.64% | +0.64 |
| ENGN Engene Holdings Inc. | New | 0.61% | +0.61 |
| GPCR Structure Therapeutics Inc. | Add +605.2% | 0.68% | +0.56 |
| COGT Cogent Biosciences Inc. | Add +16.4% | 2.51% | +0.56 |
| STOK Stoke Therapeutics Inc. | New | 0.47% | +0.47 |
| VRNA Verona Pharma Ltd. | Add +122.8% | 1.09% | +0.47 |
| TARS Tarsus Pharmaceuticals Inc. | New | 0.27% | +0.27 |
| VYNE THERAPEUTICS INC | Add +441.1% | 0.23% | +0.15 |
| SLNO Soleno Therapeutics Inc. | New | 0.15% | +0.15 |
| PCVX Vaxcyte Inc. | New | 0.05% | +0.05 |
| MTEMQ Molecular Templates Inc. | Add +75.9% | 0.18% | −0.05 |
| TELA Tela Bio Inc. | Add +28.7% | 1.16% | −0.07 |
| CLDX Celldex Therapeutics Inc. | Add +25.3% | 3.43% | −0.10 |
| CGEN Compugen Ltd. | Add +50.1% | 0.62% | −0.10 |
| OLMA Olema Pharmaceuticals Inc. | Add +6.1% | 1.46% | −0.18 |
| VCYT Veracyte Inc. | Add +0.5% | 1.51% | −0.23 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +0.5% | 1.87% | −0.36 |
| PSTX Poseida Therapeutics Inc. | Add +0.3% | 2.60% | −0.62 |
| MORF Morphic Holding Inc. | Add +0.5% | 4.09% | −0.69 |
| CCCC C4 Therapeutics Inc. | Add +0.5% | 1.65% | −1.64 |
Options Activity Q1 2024 → Q2 2024
| INSMED INC | call | New | 250,000 | $16.8M |
| MACROGENICS INC | call | Sold out | 145,500 | $2.1Mbefore exit |
| ALX ONCOLOGY HLDGS INC | put | New | 167,900 | $1.0M |
| MERSANA THERAPEUTICS INC | call | Add +9800.0% | 168,300 | $338K |
| AMYLYX PHARMACEUTICALS INC | call | Sold out | 20,000 | $57Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |